Lars B. Abrahmsen - 10 Mar 2022 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role: SVP, Chief Scientific Officer
Signature: /s/ Scott M. Coiante, attorney-in-fact
Issuer symbol: APRE
Transactions as of: 10 Mar 2022
Net transactions value: $0
Form type: 4
Filing time: 14 Mar 2022, 17:01:04 UTC
Previous filing: 05 Oct 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APRE	Common Stock	Award	$0	+24,700	+130%	$0.000000	43,700	10 Mar 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APRE	Stock Option (right to Buy)	Award	$0	+100,000		$0.000000	100,000	10 Mar 2022	Common Stock	100,000	$1.82	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 8,233 shares on March 10, 2023, (ii) 8,233 shares on March 10, 2024 and (iii) 8,234 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
F2	Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

Content

These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 8,233 shares on March 10, 2023, (ii) 8,233 shares on March 10, 2024 and (iii) 8,234 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.